Skip to main content
SpringerLink
Log in

Recent R&D Highlights

  • News & View
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Multiple myeloma is an incurable cancer of the plasma cell; plasma cells are components of the blood, and play a key role in the body’s immune response.

  2. Vioxx® (rofecoxib; Merck & Co.) and Bextra® (valdecoxib; Pfizer). Celebrex remains on the market and carries a ‘black box’ warning about the potential for cardiovascular adverse effects.

References

  1. University of Southern California. USC researchers find drug is tough tumor fighter. Media release: 29 Aug 2005

    Google Scholar 

  2. Burnham Institute. Cancer drug target Chk1 may also be source of drug resistance. Media release: 2 Sep 2005

    Google Scholar 

  3. University of Texas M. D. Anderson Cancer Center. Phase I cancer findings under-reported. Media release: 22 Aug 2005

    Google Scholar 

  4. Rosetta Inpharmatics. FDA LICENSES THE Rosetta Resolver(R) System for use in the Center for Drug Evaluation and Research. Media release: 24 Aug 2005

    Google Scholar 

  5. EurekAlert. IMEx consortium provides new mechanism for improving access to molecular interaction data. Media release: 29 Aug 2005

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 3, 17–19 (2005). https://doi.org/10.1007/BF03256994

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256994

Search

Navigation